These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 7540892)

  • 1. The pattern of emesis following high-dose cyclophosphamide and the anti-emetic efficacy of ondansetron.
    Beck TM
    Anticancer Drugs; 1995 Apr; 6(2):237-42. PubMed ID: 7540892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of oral ondansetron, a selective antagonist of 5-HT3 receptors, in the treatment of nausea and vomiting associated with cyclophosphamide-based chemotherapies. Ondansetron Study Group.
    Cubeddu LX; Pendergrass K; Ryan T; York M; Burton G; Meshad M; Galvin D; Ciociola AA
    Am J Clin Oncol; 1994 Apr; 17(2):137-46. PubMed ID: 8141105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ondansetron for nausea and vomiting associated with moderately emetogenic cancer chemotherapy.
    DiBenedetto J; Cubeddu LX; Ryan T; Kish JA; Sciortino D; Beall C; Eisenberg PD; Henderson C; Griffin D; Wentz A
    Clin Ther; 1995; 17(6):1091-8. PubMed ID: 8750400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy.
    Bonneterre J; Chevallier B; Metz R; Fargeot P; Pujade-Lauraine E; Spielmann M; Tubiana-Hulin M; Paes D; Bons J
    J Clin Oncol; 1990 Jun; 8(6):1063-9. PubMed ID: 2140854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of oral ondansetron in the prevention of emesis in outpatients receiving cyclophosphamide-based chemotherapy. The Ondansetron Study Group.
    Beck TM; Ciociola AA; Jones SE; Harvey WH; Tchekmedyian NS; Chang A; Galvin D; Hart NE
    Ann Intern Med; 1993 Mar; 118(6):407-13. PubMed ID: 8439113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerability of oral ondansetron versus prochlorperazine in the prevention of emesis associated with cyclophosphamide-based chemotherapy and maintenance of health-related quality of life.
    Crucitt MA; Hyman W; Grote T; Tester W; Madajewicz S; Yee S; Wentz A; Griffin D; Parasuraman TV; Bryson J
    Clin Ther; 1996; 18(4):778-88. PubMed ID: 8879903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and tolerability of oral ondansetron versus prochlorperazine in the prevention of emesis associated with cyclophosphamide-based chemotherapy and maintenance of health-related quality of life.
    Crucitt MA; Hyman W; Grote T; Tester W; Madajewicz S; Yee S; Wentz A; Griffin D; Parasuraman TV; Bryson J
    Clin Ther; 1996; 18(3):508-18. PubMed ID: 8829027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of ondansetron tablets in the management of chemotherapy-induced emesis: review of clinical trials.
    Beck TM
    Semin Oncol; 1992 Dec; 19(6 Suppl 15):20-5. PubMed ID: 1485178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved control of emesis and quality of life with ondansetron in breast cancer.
    Clavel M; Soukop M; Greenstreet YL
    Oncology; 1993; 50(3):180-5. PubMed ID: 8459989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 5-HT3 receptor antagonists in the control of cisplatin-induced delayed emesis.
    Ossi M; Anderson E; Freeman A
    Oncology; 1996 Jun; 53 Suppl 1():78-85. PubMed ID: 8692556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ondansetron suppository: a randomised, double-blind, double-dummy, parallel-group comparison with oral ondansetron for the prevention of cyclophosphamide-induced emesis and nausea. The Ondansetron Suppository emesis study group.
    Davidson NG; Paska W; Van Belle S; Goedhals L; McQuade B; McRae J
    Oncology; 1997; 54(5):380-6. PubMed ID: 9260599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antagonism of serotonin S3 receptors with ondansetron prevents nausea and emesis induced by cyclophosphamide-containing chemotherapy regimens.
    Cubeddu LX; Hoffman IS; Fuenmayor NT; Finn AL
    J Clin Oncol; 1990 Oct; 8(10):1721-7. PubMed ID: 2145400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
    Perez EA; Lembersky B; Kaywin P; Kalman L; Yocom K; Friedman C
    Cancer J Sci Am; 1998; 4(1):52-8. PubMed ID: 9467047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single 8 mg dose of oral ondansetron failed to prevent FAC chemotherapy-induced acute nausea and vomiting.
    Bosnjak SM; Neskovic-Konstantinovic ZB; Jovanovic-Micic DJ; Mitrovic LB; Radulovic SS
    J Chemother; 1996 Aug; 8(4):315-8. PubMed ID: 8873840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modified oral ondansetron regimen for cyclophosphamide-induced emesis in lupus nephritis.
    Yarboro CH; Wesley R; Amantea MA; Klippel JH; Pucino F
    Ann Pharmacother; 1996; 30(7-8):752-5. PubMed ID: 8826554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study.
    Perez EA; Hesketh P; Sandbach J; Reeves J; Chawla S; Markman M; Hainsworth J; Bushnell W; Friedman C
    J Clin Oncol; 1998 Feb; 16(2):754-60. PubMed ID: 9469367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High efficacy of a single oral dose of ondansetron 8 mg versus a metoclopramide regimen in the prevention of acute emesis induced by fluorouracil, doxorubicin and cyclophosphamide (FAC) chemotherapy for breast cancer.
    Bosnjak SM; Nesković-Konstantinović ZB; Radulović SS; Susnjar S; Mitrovi LB
    J Chemother; 2000 Oct; 12(5):446-53. PubMed ID: 11128567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ondansetron compared with granisetron in the prophylaxis of cyclophosphamide-induced emesis in out-patients: a multicentre, double-blind, double-dummy, randomised, parallel-group study. Emesis Study Group for Ondansetron and Granisetron in Breast Cancer Patients.
    Stewart A; McQuade B; Cronje JD; Goedhals L; Gudgeon A; Corette L; Froger X; Tubiana-Hulin M; Laplaige P; Roberts JT
    Oncology; 1995; 52(3):202-10. PubMed ID: 7715904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy-induced emesis: management of early and delayed emesis in milder emetogenic regimens.
    Barrenetxea G; Schneider J; Centeno MM; Romero H; de la Rica M; Rodríguez-Escudero FJ
    Cancer Chemother Pharmacol; 1996; 38(5):471-5. PubMed ID: 8765442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized, double-blind, dose-finding study of dexamethasone in preventing acute emesis induced by anthracyclines, carboplatin, or cyclophosphamide:
    Italian Group For Antiemetic Research
    J Clin Oncol; 2004 Feb; 22(4):725-9. PubMed ID: 14966097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.